Roche: positive long-term follow-up in lymphoma
(CercleFinance.com) - Roche reports positive results from a five-year follow-up of the pivotal phase III POLARIX study of its Polivy, at the American Society of Hematology (ASH) annual meeting, 7-10 December, in San Diego.
The analysis indicated a positive overall survival trend in favor of Polivy combined with MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHP), for previously untreated diffuse large B-cell lymphoma patients.
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, which could reduce the burden on patients and healthcare systems, the Swiss pharmaceutical company adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The analysis indicated a positive overall survival trend in favor of Polivy combined with MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHP), for previously untreated diffuse large B-cell lymphoma patients.
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, which could reduce the burden on patients and healthcare systems, the Swiss pharmaceutical company adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.